RECURSION PHARMACEUTICALS, INC. (RXRX) insider trading

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

Blake Borgeson

Director

—

$4.50M (12) scheduled

−$4.50M

6,068,287

1.13%

$23.54M

−14.3%

Christopher Gibson

Director

—

$1.98M (13) scheduled

−$1.98M

883,735

0.1651%

$3.43M

+15.9%

Najat Khan

CEO and President

—

$806.53K (4) scheduled

−$806.53K

2,072,890

0.3872%

$8.04M

+317.1%

Ben R Taylor

Chief Financial Officer

—

$157.70K (3) scheduled

−$157.70K

1,071,462

0.2001%

$4.16M

+115.8%

Robert Hershberg

Director

—

$125.00K (1) scheduled

−$125.00K

162,156

0.0303%

$629.17K

+213.6%

Namandje Bumpus

Director

—

$28.13K (2) scheduled

−$28.13K

127,632

0.0238%

$495.21K

—

Dean Y Li

Director

—

3,319,755

0.6201%

$12.88M

+4.1%

Michael Secora

Chief Financial Officer

—

1,487,694

0.2779%

$5.77M

+2.5%

David Hallett

Chief Scientific Officer

—

1,043,837

0.1950%

$4.05M

+75.7%

Tina Marriott

President and COO

—

506,852

0.0947%

$1.97M

−2.7%

Zavain Dar

Director

—

245,371

0.0458%

$952.04K

+131.0%

David J Mauro

Chief Medical Officer

—

225,429

0.0421%

$874.66K

−1.8%

Franziska Michor

Director

—

215,477

0.0403%

$836.05K

—

Fred Hassan

Director

—

156,658

0.0293%

$607.83K

—

Elaine D Sun

Director

—

135,981

0.0254%

$527.61K

—

RECURSION PHARMACEUTICALS, INC.

What the insiders did Scheduled selling only

By person